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Background.  —  The  effect  of  statins  on  the  prevention  of  cardiovascular  events  is  well-
established.  However,  a  recent  controversy  in  France  questioned  the  value  of  statins,  especially
in primary  prevention.
Aims.  —  To  evaluate  the  impact  of  this  controversy  on  patient  adherence  to  statin  therapy  and
its potential  clinical  impact.
Methods.  —  All  patients  on  statins  were  recruited  consecutively  from  consultations  over  a  period
of 1  month  (from  March  2013)  by  ﬁve  physicians  in  three  centres.  Patient  demographics  and  co-
morbidities  were  collected  and  adherence  to  statin  therapy  was  evaluated  with  a  questionnaire.
We estimated  the  number  of  deaths  and  major  cardiovascular  events  that  could  be  induced  per
year.
Results. —  A  total  of  142  patients  were  included:  37  in  primary  prevention  (mean  age,
68.0 ±  13.1  years;  41%  women);  105  in  secondary  prevention  (mean  age,  67.6  ±  12.1  years;
20% women).  In  primary  prevention,  24.3%  of  patients  intended  to  stop  statins  versus  8.6%  in
Abbreviations: BMI, Body Mass Index; CABG, Coronary Artery Bypass Graft; LDL, Low-Density Lipoprotein; MI, Myocardial Infarction; PCI,
Percutaneous Coronary Intervention.
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secondary  prevention  (P  <  0.001).  In  France,  if  the  percentages  of  medication  discontinuations
following  the  controversy  were  actually  similar  to  those  we  found  in  our  survey,  4992  major
cardiovascular  events,  including  1159  deaths,  would  be  induced  in  1  year.
Conclusion.  —  Recent  controversy  over  statins  could  induce  a  large  proportion  of  patients  to
stop their  medication  and  generate  a  large  number  of  major  cardiovascular  events.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Contexte.  —  Les  bénéﬁces  des  statines  sur  la  prévention  des  événements  cardiovasculaires  sont
aujourd’hui  bien  démontrés.  Récemment,  en  France,  une  polémique  a  remis  en  cause  l’intérêt
des statines,  notamment  en  prévention  primaire.
Objectif.  —  Évaluer  l’impact  de  cette  polémique  sur  l’observance  des  patients  vis-à-vis  des
statines.
Méthodes.  —  Tous  les  patients  sous  statines  ont  été  recrutés  consécutivement  en  consultations
pendant  une  période  de  1  mois  (en  mars  2013)  par  5  cardiologues  au  sein  de  3  centres.  Les  carac-
téristiques  démographiques,  les  comorbidités  ont  été  collectées  et  l’adhérence  aux  statines
évaluée par  un  questionnaire.  Nous  avons  estimé  le  nombre  de  décès  et  d’événements  cardio-
vasculaires  majeurs  que  cette  polémique  pourrait  engendrer  à  partir  des  données  actuelles.
Résultats.  —  Cent-quarante  patients  ont  été  inclus:  37  en  prévention  primaire  (âge  moyen,
68,0 ±  13,1  ;  41  %  femme);  105  en  prévention  secondaire  (âge  moyen,  67,6  ±  12,1  ;  20  %  femme).
En prévention  primaire,  24,3  %  des  patients  interrogés  ont  déclaré  avoir  l’intention  d’arrêter
les statines  contre  8,6  %  prévention  secondaire  (p  <  0,001).  En  France,  cette  polémique  pour-
rait engendrer  4992  événements  cardiovasculaires  majeurs  dont  1159  décès  par  an  si  les  patients
arrêtent  réellement  leur  statine.
Conclusion.  —  La  polémique  récente  sur  les  statines  pourrait  entraîner  l’arrêt  de  ces  traite-
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andomized  controlled  clinical  trials  and  meta-analyses
ave  shown  statins  to  be  beneﬁcial  in  decreasing  morbid
nd  mortal  cardiovascular  events  in  apparently  healthy  indi-
iduals  and  in  those  with  clinically  evident  cardiovascular
isease  [1—6].  However,  a  recent  controversy  in  France
uestioned  the  value  of  statins,  especially  in  primary  pre-
ention,  in  which  the  cost-effectiveness  of  treatment  is
ore  complex  to  assess  [7—9].  Therefore,  we  aimed  to  eval-
ate  the  impact  of  this  controversy  on  patient  adherence  to
tatin  therapy  and  its  potential  clinical  impact.
ethods
atient population
ll  patients  on  statins  were  recruited  consecutively  from
utpatient  consultations  over  a  period  of  1  month  (from
arch  2013)  by  ﬁve  physicians  (L.S.,  L.P.,  D.B.,  N.D.  and
.P.)  in  three  centres  (including  two  university  hospitals  and
ne  private  centre).
Patients  were  included  regardless  of  the  type  of  cardio-
ascular  event  prevention  (primary  or  secondary).ata collection
ata  were  recorded  on  dedicated  questionnaires  at  each




rs  droits  réservés.
ommon  database.  The  following  data  were  prospectively
ollected  and  electronically  stored  for  each  patient:  demo-
raphic  characteristics  (age,  sex  and  body  mass  index  [BMI]),
ardiovascular  risk  factors  (arterial  hypertension,  diabetes,
urrent  smoking,  hyperlipidaemia)  and  medical  cardiovas-
ular  history  (presence  of  prior  acute  myocardial  infarction
MI],  prior  percutaneous  coronary  intervention  [PCI],  prior
oronary  artery  bypass  graft  [CABG],  peripheral  artery  dis-
ase,  chronic  kidney  disease).  Chronic  kidney  disease  was
eﬁned  as  creatinine  clearance  <  30  mL/minute  or  creati-
ine  <  15  mg/L.
Regarding  adherence  to  statin  therapy,  for  each  patient
e  collected  the  indication  for  statin  treatment  (primary
r  secondary  prevention)  and  the  type,  dose,  duration  and
otential  side-effects  of  the  statin  used.
During  the  consultation,  the  physician  initially  did  not
llude  to  the  statin  controversy,  in  order  to  assess  whether
he  patient  mentioned  it  spontaneously;  if  they  did  not,  the
hysician  asked  the  patient  at  the  end  of  the  consultation
hether  they  had  heard  of  the  controversy.  In  all  cases,
atients  were  asked  whether  they  intended  to  stop  their
tatin  treatment  as  a  consequence  of  the  controversy.
ne-year potential clinical impact
or  this  study,  we  made  the  conservative  assumption  that
atients  stopping  statins  would  have  a  1  mmol/L  increase
n  low-density  lipoprotein  (LDL)  (the  average  effect  of  the
owest  dose  of  any  statin  available  is  about  a  1.5  mmol/L
eduction  in  LDL)  [10]. Using  the  Cholesterol  Treatment
Controversy  over  statins  513
Table  1  Baseline  characteristics  according  to  type  of  prevention.
Primary  prevention  Secondary  prevention  P
(n  =  37)  (n  =  105)
Age  (years)  68.0  ±  13.1  67.6  ±  12.1  0.86
Women  15  (41)  21  (20)  0.01
BMI  (kg/m2)  25.8  ±  4.2  26.5  ±  6.8  0.58
Hypertension  31  (84)  60  (66)  0.04
Diabetes  mellitus 8  (22) 33  (31)  0.26
Current  smoking 2  (5) 16  (15) 0.12
Hyperlipidaemia  30  (81) 75  (74) 0.36
Previous  MI 0  (0) 66  (63) <  0.001
Previous  PCI  0  (0)  69  (66)  <  0.001
Previous  CABG  0  (0)  20  (19)  0.004
Peripheral  artery  disease  0  (0)  10  (10)  0.05
Chronic  renal  insufﬁciency  9  (24)  18  (17)  0.34
Data are presented as mean ± standard deviation or number (%); BMI: body mass index; CABG: coronary artery bypass graft; MI: myocardial


























dTrialists’  collaboration  meta-analysis  [7]  and  data  from
the  National  Health  Insurance  System  on  statin  consump-
tion  according  to  the  presence  of  cardiovascular  history
[11],  we  evaluated  the  potential  clinical  impact  of  this
controversy  in  terms  of  cardiovascular  events  (includ-
ing  death,  non-fatal  MI  or  stroke)  and  cardiovascular
death.
In  primary  prevention,  the  National  Health  Insurance
System  estimated  that  8.7%  people  used  statins  in  France
(i.e.  5046  million).  Results  of  the  meta-analysis  showed  a
reduction  of  1.44  cardiovascular  events  per  100  person-
years  on  statins  (risk  reduction,  25%  per  mmol)  and  0.53
cardiovascular  deaths  per  100  person-years  (risk  reduction,
15%).
In  secondary  prevention,  the  National  Health  Insurance
System  estimated  that  70.7%  people  used  statins  in  France
(i.e.  1218  million).  Results  of  the  meta-analysis  showed  a
reduction  of  3.27  cardiovascular  events  per  100  person-
years  on  statins  (risk  reduction,  21%  per  mmol)  and  1.76
cardiovascular  deaths  per  100  person-years  (risk  reduction,
12%).
Statistical analysis
Statistical  analyses  were  performed  using  Stata  software
(version  12;  StataCorp  LP,  College  Station,  TX,  USA)  or  SPSS
software  (version  20.0;  IBM,  Armonk,  NY,  USA).  For  quantita-
tive  variables,  means,  standard  deviations  and  minimum  and
maximum  values  were  calculated.  In  addition,  medians  with
interquartile  ranges  were  calculated  for  some  variables.  Dis-
crete  variables  are  presented  as  percentages.  Comparisons
were  made  using  the  chi-square  test  or  Fisher’s  exact  test  for
discrete  variables  and  using  unpaired  t-tests,  the  Wilcoxon
signed-rank  test  or  one-way  analyses  of  variance  for  contin-
uous  variables.  Odds  and  hazard  ratios  are  given  with  their
95%  conﬁdence  intervals.  For  all  analyses,  a  P  value  <  0.05





ver  a 1  month  period,  a  total  of  142  patients  were  included
n  this  study.
aseline characteristics
aseline  clinical  characteristics  of  patients  on  statins
ccording  to  the  type  of  prevention  are  summarized  in
able  1.  Most  patients  were  followed  for  secondary  pre-
ention  (74%).  The  mean  age  was  similar  in  both  groups.
he  proportion  of  women  was  higher  in  primary  prevention.
n  addition,  the  proportions  of  diabetes,  current  smoking,
yperlipidaemia,  obesity  (BMI  > 30  kg/m2)  and  chronic  renal
nsufﬁciency  were  similar  in  both  groups;  however,  more
atients  on  statins  for  primary  prevention  had  hypertension.
articipating centres
atients  were  enrolled  by  ﬁve  physicians  (cardiologists)  in
hree  hospitals:  two  university  hospitals  (the  Necker  Hospi-
al  and  the  Georges-Pompidou  European  Hospital,  in  Paris)
nd  one  private  centre  (in  Issy-les-Moulineaux).  No  signiﬁ-
ant  difference  was  observed  according  to  centre.
mpact of statin controversy
verall,  23%  of  patients  spontaneously  talked  of  the  con-
roversy  over  statins  during  the  consultation  and  68%  were
ware  of  it.  No  difference  was  observed  in  terms  of  the  type
f  prevention  (27%  vs  22%,  P  =  0.53  and  62%  vs  70%,  P  =  0.75,
espectively).  In  primary  prevention,  19%  of  patients  had
oubts  about  the  beneﬁts  of  treatment  versus  10%  in  sec-
ndary  prevention  (P  =  0.13).  Sixty-ﬁve  percent  of  patients
greed  to  take  generic  drugs  and  53%  reported  reading
atient  information  leaﬂets  for  their  medications  (no  dif-
erence  in  terms  of  the  type  of  prevention).
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Table  2  Statin  therapy  according  to  type  of  prevention.
Primary  prevention  Secondary  prevention  P
(n  =  37)  (n  =  105)
Statins  used
Atorvastatin  11  (30)  31  (29.5)
Fluvastatin  2  (5)  3  (3)
Pravastatin  7  (19)  10  (9.5)
Rosuvastatin 15  (41) 46  (44)
Simvastatin  0  (0) 15  (14)
Ezetimibea 2  (5) 9  (9)
Adverse  events:  muscular  weakness,  stiffness  or  pain 10 (27) 21  (20) 0.37
LDL  cholesterol  (mg/L)  108  (95—137)  82  (64—101)  <  0.001

































aAlone or with statin.
All  patients  had  statins  for  primary  or  secondary  pre-
ention  (Table  2).  Rosuvastatin  and  atorvastatin  were  the
ost  commonly  used  statins,  whatever  the  type  of  pre-
ention.  Ezetimibe  was  used  in  5%  for  primary  prevention
nd  in  9%  for  secondary  prevention.  Adverse  events  (mus-
ular  weakness,  stiffness  or  pain)  were  reported  in  27%  in
rimary  prevention  and  in  21%  in  secondary  prevention.
he  median  LDL  cholesterol  concentration  was  108  mg/L
interquartile  range,  95—137)  in  primary  prevention  and
2  mg/L  (interquartile  range,  64—101)  in  secondary  preven-
ion.
Finally,  24.3%  people  using  statins  in  primary  prevention
ntended  to  stop  their  medication  versus  8.6%  in  secondary
revention  (P  <  0.001)  (Fig.  1).  However,  very  few  patients
ad  actually  stopped  their  medication  before  the  consul-
ation.  Among  these  patients,  no  difference  was  observed
ccording  to  age  group  (<  60,  60—74,  ≥  75  years)  and  80%
ere  women  in  primary  prevention  while  80%  were  men  in
econdary  prevention.
igure 1. Proportion of patients with the intention to stop statin



















pPatients  who  intended  to  stop  statin  therapy  were  more
ften  women,  had  less  cardiovascular  disease  and  had  more
dverse  events  associated  with  statins  (Table  3).
otential clinical impact
n  primary  prevention,  on  a  national  scale  and  based  upon
he  Cholesterol  Treatment  Trialists’  results,  one  can  calcu-
ate  that  18,000  events  are  avoided  by  statin  treatment  per
ear,  including  3970  deaths.  If  24%  of  patients  stopped  their
edication,  4320  events  would  be  induced,  including  953
dditional  deaths  in  1  year.
In  secondary  prevention,  it  can  be  estimated  that  8400
vents  are  avoided  by  statin  treatment  each  year  in  France,
ncluding  2580  deaths.  If  8%  of  patients  stopped  their
edication,  672  events  would  be  induced,  including  206
dditional  deaths  in  1  year.
Overall,  4992  events  would  thus  be  generated,  including
159  additional  deaths  in  1  year.
iscussion
he  present  study  demonstrated  that  a  large  proportion  of
atients  using  statins  are  at  risk  of  stopping  their  medica-
ion  after  the  recent  controversy  over  statins  in  France.  If
hey  actually  did  so,  this  controversy  could  generate  approx-
mately  5000  major  cardiovascular  events  per  year,  including
ver  1100  deaths.  In  addition,  our  data  conﬁrm  the  impact
hat  media  can  have  on  public  health  issues  [10,12,13].
As  might  be  expected,  our  results  showed  that  the  pro-
ortion  of  patients  intending  to  stop  statin  therapy  differed
ccording  to  the  type  of  prevention.  The  beneﬁts  of  statins
n  secondary  prevention  after  cardiovascular  events  are
ell-documented  [8,14—17]  and  statins  are  recommended
ith  a  high  level  of  evidence  in  the  current  guidelines
18,19].  In  addition,  patients  are  more  aware  of  the  poten-
ial  importance  of  treatment  compared  with  in  primary
revention.  Therefore,  the  proportion  of  such  patients  who
ould  stop  their  treatment  was  small  (<  10%).
The  use  of  statins  in  primary  prevention  is  more  com-
lex  and  the  cost-effectiveness  is  more  controversial.  Some
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Table  3  Baseline  characteristics  according  to  intention  to  stop  statin  therapy.
Intention  to  stop
statin  therapy
No  intention  to  stop
statin  therapy
P
(n  =  18)  (n  =  123)
Age  (years)  67.6  ±  12.6  67.7  ±  12.3  0.48
Women  9  (50)  27  (22)  0.01
BMI  (kg/m2)  23.1  ±  4.0  26.8  ±  6.3  0.01
Hypertension  13  (72) 87  (70) 0.86
Diabetes  mellitus 3  (17) 38  (31) 0.22
Current  smoking 2  (11) 16  (13) 0.83
Hyperlipidaemia  14  (78)  91  (75)  0.81
Previous  MI  5  (28)  62  (50)  0.08
Previous  PCI  4  (22)  65  (52)  0.02
Previous  CABG  4  (22)  16  (13)  0.30
Peripheral  artery  disease  1  (6)  9  (7)  0.79
Chronic  renal  insufﬁciency  3  (17)  24  (19)  0.79
Adverse  events:  muscular  weakness,
stiffness  or  pain
9 (50)  22  (18)  <  0.001
LDL  cholesterol  (mg/L)  120  (93—148)  85  (68—104)  <  0.001
Data are presented as mean ± standard deviation, number (%) or median (interquartile range); BMI: body mass index; CABG: coronary





























tphysicians  are  not  convinced  that  medications  such  as  statins
should  be  used  at  all  for  primary  prevention,  as  evidenced
by  the  current  debate.  This  probably  explains  why  one  of
four  patients  surveyed  wanted  to  stop  their  statins  after
the  global  media  campaign  suggesting  that  these  medica-
tions  could  be  harmful.  Of  note,  all  patients  who  were
ready  to  stop  their  treatment  reported  side-effects  (mus-
cular  weakness,  stiffness  or  pain),  which  could  encourage
them  to  stop  their  medication  and  constitute  a  confound-
ing  factor.  However,  several  sources,  including  randomized
trials  and  meta-analyses,  have  demonstrated  the  beneﬁts  of
statin  therapy  in  this  indication  [4,6—9,20].  In  the  last  meta-
analysis  published  in  the  Cochrane  Database  [20], which
included  18  randomized  trials  (56,934  patients),  Taylor  et  al.
showed  that  all-cause  mortality  and  fatal  and  non-fatal  car-
diovascular  events  were  signiﬁcantly  reduced  with  the  use
of  statins  in  primary  prevention  (9.3%  vs  12.2%;  relative  risk
0.75;  95%  conﬁdence  interval  0.70—0.81).  Of  1000  patients
treated  with  a  statin  for  5  years,  18  would  avoid  a  major
cardiovascular  event,  which  compares  well  with  other  treat-
ments  used  for  preventing  cardiovascular  disease.
The  current  controversy  concerns  especially  the  use
of  statins  in  primary  prevention  for  people  at  low  risk
of  vascular  disease.  Another  meta-analysis  of  individual
data  from  27  randomized  trials  published  in  The  Lancet
[8]  showed  that  reduction  of  LDL  cholesterol  with  statin
therapy  signiﬁcantly  reduced  the  risk  of  major  vascular
events  in  individuals  with  a  5-year  risk  <  10%  (in  whom  the
mean  risks  were  2.6%  for  major  coronary  events  plus  3%
for  other  major  vascular  events),  even  in  those  with  no
previous  history  of  vascular  disease,  diabetes  or  chronic
kidney  disease.  In  addition,  they  also  demonstrated  that
statins  are  indeed  both  cost-effective  and  safe  for  people
with  a  5-year  risk  of  major  vascular  events  <  10%,  which  is




rherefore  cost-effective  in  primary  prevention,  including
or  people  at  low  risk  of  vascular  disease.
Finally,  in  the  current  context  of  growing  suspicion  of
harmaceutical  companies,  patients  are  becoming  more
eluctant  to  use  long-term  medications.  Therefore,  it  is  cru-
ial  to  inform  patients  correctly  about  medical  management
to  explain  the  beneﬁt/risk  balance  for  each  decision)  and  to
e  careful  with  messages  that  are  given  to  the  population.
egarding  statins,  the  current  controversy  could  be  dramatic
nd  could  generate  a  large  number  of  major  cardiovascular
vents.  In  addition,  previous  health  communication  research
as  documented  the  importance  of  the  news  media’s  inﬂu-
nce  on  the  public’s  health-related  perceptions  and  health
ehaviours  [10,12,13].  Therefore,  our  study  suggests  that
uture  educational  efforts,  based  on  unquestionable  scien-
iﬁc  evidence,  may  be  needed  to  overcome  the  politicized
ontext  and  avoid  a negative  public  health  impact.
Our  study  has  obvious  limitations.  The  cohort  studied
as  small  and  we  cannot  be  certain  that  it  is  represen-
ative  of  the  French  population.  However,  if  anything,  it
s  likely  that  patients  followed  by  cardiologists  are  more
health-sensitive’  than  patients  who  do  not  seek  specialist
dvice;  therefore,  the  impact  of  the  public  controversy
hat  we  observed  might  be  an  underestimation.  In  fact,
n  the  general  population,  including  numerous  people  not
eferred  to  cardiologists,  the  controversy  might  lead  to
ven  greater  rates  of  treatment  discontinuation  than  those
hat  we  observed.  Conversely,  to  calculate  the  number  of
otential  major  cardiovascular  events,  we  assumed  that
atients  who  intended  to  stop  statins  had  really  stopped
hem  and  that  all  other  patients  continued  to  take  their
edication.  It  is  known,  however,  that  about  25%  of  the
atients  on  statin  treatment  after  an  acute  MI  are  poorly
dherent  to  their  treatment  [24].  Some  of  the  patients  who













































ave  done  so  independently  of  the  controversy;  this  is  not
ikely  to  be  a  major  confounder,  however,  as  most  of  our
atients  had  been  on  statin  therapy  for  a  very  long  time
nd  were  good  adherers  to  their  treatment  up  until  then.
verall,  it  is  likely  that  a  fair  proportion  of  the  patients
ho  reported  intending  to  stop  their  medication  might
ctually  have  continued  to  take  it,  after  considering  the
dvice  of  their  cardiologist.  Conversely,  stopping  one  class
f  medication  might  also  encourage  patients  to  stop  other
reatments,  such  as  antiplatelet  therapy,  and  then  increase
he  number  of  major  cardiovascular  events.
onclusion
ecent  controversy  over  statins  could  induce  a  large  pro-
ortion  of  patients  to  stop  their  medication  and  generate  a
arge  number  of  major  cardiovascular  events.  In  the  present
ontext  of  suspicion  regarding  all  medications,  it  is  crucial  to
e  careful  with  messages  delivered  to  the  population  and  to
ake  time  to  explain  to  patients  the  expected  beneﬁts  of  all
edications  they  are  prescribed.  Future  educational  efforts
ay  be  needed  to  overcome  the  inappropriately  politicized
ontext  of  public  health  issues.
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